US 12,460,003 B2
Methods of assessing and treating cancer in subjects having dysregulated lymphatic systems
Michael David Kuo, Scottsdale, AZ (US); and Ching-Yu Huang, Scottsdale, AZ (US)
Assigned to Ensemble Group Holdings, Scottsdale, AZ (US)
Filed by Ensemble Group Holdings, Scottsdale, AZ (US)
Filed on Nov. 12, 2020, as Appl. No. 17/096,513.
Application 17/096,513 is a continuation of application No. 16/155,726, filed on Oct. 9, 2018, granted, now 10,870,702.
Application 16/155,726 is a continuation of application No. PCT/US2017/053504, filed on Sep. 26, 2017.
Claims priority of provisional application 62/412,488, filed on Oct. 25, 2016.
Claims priority of provisional application 62/399,766, filed on Sep. 26, 2016.
Prior Publication US 2021/0070859 A1, Mar. 11, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61B 5/00 (2006.01); A61B 5/055 (2006.01); A61B 6/03 (2006.01); A61K 31/4375 (2006.01); A61P 35/00 (2006.01); C07K 16/22 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2818 (2013.01) [A61B 5/055 (2013.01); A61B 5/418 (2013.01); A61B 6/032 (2013.01); A61B 6/037 (2013.01); A61K 31/4375 (2013.01); A61P 35/00 (2018.01); C07K 16/22 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); A61K 2039/545 (2013.01); C07K 2317/76 (2013.01)] 14 Claims
 
1. A method to treat cancer in a human subject in need of inhibition of lymphangiogenesis, comprising:
a. administering to the subject, who had been determined to have a dysregulated lymphatic system, a therapeutically effective amount of a first monoclonal antibody chosen from pembrolizumab and nivolumab, thereby inducing an immune modifying effect in the subject; and
b. further administering to the subject, a therapeutically effective amount of a second monoclonal antibody, before or concurrent with the administration of the first monoclonal antibody, wherein the second monoclonal antibody binds to the extracellular domain of VEGFR-3, and wherein the second monoclonal antibody inhibits the lymphangiogenesis in the subject.